EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

Marina C Garassino iD, Shirish Gadgeel iD, Giovanna Speranza, Enriqueta Felip iD, Emilio Esteban, Manuel Dómine iD, Maximilian J Hochmair, Steven F Powell iD, Helge G Bischoff, Nir Peled iD, Francesco Grossi iD, Ross R Jennens iD und 9 weitere

Journal of Clinical Oncology · 10.04.2023 · 41 (11) · 1992-1998

DOI: 10.1200/jco.22.01989 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.04.2023. Verfasst von Marina C Garassino und 20 weiteren Autor:innen. Beteiligte Einrichtung: Knapp Center for Biomedical Discovery, University of Chicago Medicine & Biological Sciences, Chicago, IL. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 734-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically on the based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We present 5-year outcomes from the phase 3 KEYNOTE-189 study (ClinicalTrials.gov identifier: NCT02578680 ). Eligible patients with previously untreated metastatic nonsquamous non–small-cell lung cancer without EGFR/ALK alterations were randomly assigned 2:1 to pembrolizumab 200 mg or placebo once every 3 weeks for up to 35 cycles with pemetrexed and investigator's choice of carboplatin/cisplatin for four cycles, followed by maintenance pemetrexed until disease progression or unacceptable toxicity. Primary end points were overall survival (OS) and progression-free survival (PFS). Among 616 randomly assigned patients (n = 410, pembrolizumab plus pemetrexed-platinum; n = 206, placebo plus pemetrexed-platinum), median time from random assignment to data cutoff (March 8, 2022) was 64.6 (range, 60.1-72.4) months. Hazard ratio (95% CI) for OS was 0.60 (0.50 to 0.72) and PFS was 0.50 (0.42 to 0.60) for pembrolizumab plus platinum-pemetrexed versus placebo plus platinum-pemetrexed. 5-year OS rates were 19.4% versus 11.3%. Toxicity was manageable. Among 57 patients who completed 35 cycles of pembrolizumab, objective response rate was 86.0% and 3-year OS rate after completing 35 cycles (approximately 5 years after random assignment) was 71.9%. Pembrolizumab plus pemetrexed-platinum maintained OS and PFS benefits versus placebo plus pemetrexed-platinum, regardless of programmed cell death ligand-1 expression. These data continue to support pembrolizumab plus pemetrexed-platinum as a standard of care in previously untreated metastatic non–small-cell lung cancer without EGFR/ALK alterations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansPemetrexedPlatinumErbB ReceptorsReceptor Protein-Tyrosine KinasesAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, Humanized

Substanzen

PemetrexedPlatinumErbB ReceptorsReceptor Protein-Tyrosine KinasespembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Knapp Center for Biomedical Discovery, University of Chicago Medicine & Biological Sciences, Chicago, IL.
  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Henry Ford Cancer Institute/Henry Ford Health, Detroit, MI.
  • Centre Integré de Cancérologie de la Montérégie, Hôpital Charles-Le Moyne, Greenfield Park, QC, Canada.
  • Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain.

ORCID-Profile: Marina C Garassino, Shirish Gadgeel, Enriqueta Felip, Manuel Dómine, Steven F Powell, Nir Peled, Francesco Grossi, Ross R Jennens, Martin Reck, Edward B Garon, Takayasu Kurata, Delvys Rodríguez-Abreu

Zitieren

APA

Garassino, M. C., Gadgeel, S., Speranza, G., Felip, E., Esteban, E., Dómine, M., Hochmair, M. J., Powell, S. F., Bischoff, H. G., Peled, N., Grossi, F., Jennens, R. R., Reck, M., Hui, R., Garon, E. B., Kurata, T., Gray, J. E., Schwarzenberger, P., Jensen, E., …, & Rodríguez-Abreu, D. (2023). Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. Journal of Clinical Oncology, 41(11), 1992-1998. https://doi.org/10.1200/jco.22.01989

Vancouver

Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, Dómine M, et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. Journal of Clinical Oncology. 2023;41(11):1992-1998. doi:10.1200/jco.22.01989

BibTeX
@article{Garassino2023,
  author = {Garassino, Marina C and Gadgeel, Shirish and Speranza, Giovanna and Felip, Enriqueta and Esteban, Emilio and Dómine, Manuel and Hochmair, Maximilian J and Powell, Steven F and Bischoff, Helge G and Peled, Nir and Grossi, Francesco and Jennens, Ross R and Reck, Martin and Hui, Rina and Garon, Edward B and Kurata, Takayasu and Gray, Jhanelle E and Schwarzenberger, Paul and Jensen, Erin and Pietanza, M Catherine and Rodríguez-Abreu, Delvys},
  title = {Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {11},
  pages = {1992--1998},
  doi = {10.1200/jco.22.01989}
}
Kostenlos starten →